REACT: New site to bring jobs back to Ulverston PLANS to build a £350m bio-manufacturing plant to produce modern medicines has taken a major step forward much to the delight of the community. Lakes BioScience, formed from a team of UK industry experts, has been granted planning permission to start work on the site at Ulverston. This will generate 250 high-value, high-tech jobs at a state-of-the-art factory producing monoclonal antibodies. Dan Ladden said: Good luck to them. I hope they can recruit locally. Ian Betty said: Great news, well done SLDC for not holding things up and sending out a positive message. Thanks to Lakes Bio Science for having confidence in our area. Thanks to GSK for the land. Not just jobs, it’s the status of them. If they are hard to get its encouragement for young people to get educated and stay in the area. It’s a win win, if locals can’t take them up then it will attract well qualified people to the area.”
Sarah Townsend
A company called Lakes BioScience has been granted planning permission to start preparatory work to build a biomanufacturing facility to produce medicines at a site in Cumbria.
South Lakeland Council awarded consent for groundworks to begin on the project, which would sit close to Glaxosmithkline’s current Ulverston factory on South Lonsdale Road, which the pharmaceutical giant expects to close over the next four years, it announced last week.
Lakes BioScience, formed from a team of UK industry experts, intends to build its plant on land owned by GSK and which GSK pledged to donate to the community for local economic development uses after ditching its own plans to build a new pharmaceutical factory on the site in 2017.
Plans to build a £350m biomanufacturing plant to produce modern medicines and boost the UK’s resilience have taken a major step forward. Lakes BioScience, formed from a team of UK industry experts, has been granted planning permission to start work on the site in Ulverston. The proposals will create 250.